LAUSR

Graphical abstract Figure. No Caption available. Abstract The current study was designed to develop and optimize lazaroid loaded nano‐structured lipid carriers (LAZ‐NLCs) using design of experiment approach for enhancing lazaroid brain exposure. Response surface plots were used to determine the effects of independent variables (amount of PEGylating agent and liquid lipid) on dependent variables (particle size, zeta potential and encapsulation efficiency), while numerical optimization was used for optimizing LAZ‐NLCs composition. The optimal LAZ‐NLCs were spherical in shape with measured size of 172.3 ± 3.54 nm, surface charge of −4.54 ± 0.87 mV and encapsulation efficiency of 85.01 ± 2.60%. The optimal LAZ‐NLCs were also evaluated for hemolytic potential, storage stability and solid‐state properties. The plasma pharmacokinetics along with brain and hepatic distributions of control lazaroid citrate solution and optimal LAZ‐NLCs formulation were evaluated in Sprague‐Dawley rats after the single bolus intravenous administration. The optimized LAZ‐NLCs and the control lazaroid citrate solution had similar plasma pharmacokinetic profiles; however, differential organ bio‐distributions were observed. The lazaroid exposure in brain was enhanced by two times with a decreased liver exposure by half for the NLCs group compared to the solution group.